Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0)1300 321501 or Email: reportstore@bioportfolio.com 2
Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Summary Nektar Therapeutics (Nektar) is a biopharmaceutical company. It carries out discovery and development of a pipeline of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. Nektar s technology platformns offers a wide array of functional attributes, which optimizes and enhances the profile of wide range of molecules including many classes of drugs targeting numerous disease areas. The company s products focuses on various therapeutic areas, including, cancer, pain, anti-infectives, anti-viral and immunology among others. Its research and development activities involve peptides, small molecule drugs, and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US. Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma etrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of 3
the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Additional Details Publisher : Global Data Reference : GDPH4344D Number of Pages : 29 Report Format : PDF Publisher Information : 4
5
Table Of Contents for Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Table of Contents Table of Contents 2List of Tables 3List of Figures 4Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10Nektar Therapeutics, Pharmaceuticals & Healthcare, Deal Details 11Partnerships 11Bristol-Myers Squibb Company Enters into Agreement with Nektar Therapeutics 11Licensing Agreements 12Nektar Therapeutics Enters into Licensing Agreement with Daiichi Sankyo Europe for Onzeald 12Equity Offering 14Nektar Therapeutics Prices Public Offering of Shares for USD175.5 Million 14Nektar Therapeutics Completes Public Offering Of Shares For US$124.6 Million 16Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For US$225 Million 17Debt Offering 19Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 19Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For US$125 Million 21Asset Transactions 23RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 23Nektar Therapeutics - Key Competitors 25Key Employees 26Locations And Subsidiaries 28Head Office 28Other Locations & Subsidiaries 28Appendix 29Methodology 29About GlobalData 29Contact Us 29Disclaimer 29 6
List Of Tables in Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile List of Tables Nektar Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2015 1 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5 Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7 Nektar Therapeutics, Deals By Therapy Area, 2010 to YTD 2016 8 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10 Bristol-Myers Squibb Company Enters into Agreement with Nektar Therapeutics 11 Nektar Therapeutics Enters into Licensing Agreement with Daiichi Sankyo Europe for Onzeald 12 Nektar Therapeutics Prices Public Offering of Shares for USD175.5 Million 14 Nektar Therapeutics Completes Public Offering Of Shares For US$124.6 Million 16 Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For US$225 Million 17 Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 19 Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For US$125 Million 21 RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 23 Nektar Therapeutics, Key Competitors 25 Nektar Therapeutics, Key Employees 26 Nektar Therapeutics, Other Locations 28 Nektar Therapeutics, Subsidiaries 28 7
List Of Figures, Charts and Diagrams in Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile List of Figures Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7 Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8 8
How to Buy... Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Email: Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $250 Single User Price $500 Site License Price $750 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will email you the invoice with a payment link) Direct Wire Transfer (we will email you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0)1300 321501 We will be delighted to give you our personal attention. 9